Effects of Erchen Decoction on PHGDH methylation and the PHGDH-mediated serine metabolism signaling pathway in mice with dyslipidemia of the phlegm-dampness obstruction syndrome
|更新时间:2026-04-08
|
Effects of Erchen Decoction on PHGDH methylation and the PHGDH-mediated serine metabolism signaling pathway in mice with dyslipidemia of the phlegm-dampness obstruction syndrome
Beijing Journal of Traditional Chinese MedicineVol. 45, Issue 2, Pages: 190-195(2026)
CHEN Xinyi,XUE Xiaolin,YE Chao,et al.Effects of Erchen Decoction on PHGDH methylation and the PHGDH-mediated serine metabolism signaling pathway in mice with dyslipidemia of the phlegm-dampness obstruction syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(02):190-195.
CHEN Xinyi,XUE Xiaolin,YE Chao,et al.Effects of Erchen Decoction on PHGDH methylation and the PHGDH-mediated serine metabolism signaling pathway in mice with dyslipidemia of the phlegm-dampness obstruction syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2026,45(02):190-195. DOI: 10.16025/j.1674-1307.2026.02.007.
Effects of Erchen Decoction on PHGDH methylation and the PHGDH-mediated serine metabolism signaling pathway in mice with dyslipidemia of the phlegm-dampness obstruction syndrome
on 3-phosphoglycerate dehydrogenase (PHGDH) methylation and the PHGDH-mediated serine metabolism signaling pathway in mice with dyslipidemia phlegm-dampness obstruction syndrome.
Methods
2
C57BL/6J mice were used as the normal group. Twenty ApoE knockout mice were selected using a random number table method to establish a model of dyslipidemia with phlegm-dampness obstruction syndrome, and five ApoE knockout mice were used to establish a model of dyslipidemia with spleen-kidney
yang
deficiency syndrome. After successful modeling, the ApoE knockout mice were randomly divided into a model group, a prescription-syndrome corresponding low-dose group, a prescription-syndrome corresponding medium-dose group, a prescription-syndrome corresponding high-dose group, and a prescription-syndrome non-corresponding group, with 5 mice in each group. The prescription-syndrome corresponding low-, medium-, and high-dose groups were administered
Erchen Decoction
by gavage at doses of 4.45, 8.90, and 17.8 g/(kg·d), respectively. The prescription-syndrome non-corresponding group received
Erchen Decoction
at 8.90 g/(kg·d). The normal and model groups were given an equal volume of normal saline by gavage. All groups were treated once daily for 4 weeks. Serum PHGDH levels were measured by enzyme-linked immunosorbent assay (ELISA). The methylation level of the PHGDH gene in aortic tissue was determined by methylation-sensitive restriction endonuclease polymerase chain reaction (MSRE-PCR). The mRNA expression level of PHGDH in aortic tissue was measured by reverse transcription polymerase chain reaction (RT-PCR). Serum levels of key metabolites in the serine metabol
ism pathway were detected by liquid chromatography-mass spectrometry (LC-MS).
Results
2
Compared with the normal group, the model group showed higher methylation levels of the PHGDH gene and lower PHGDH mRNA expression and serum PHGDH levels (
P
<
0.05). Compared with the model group, the prescription-syndrome corresponding medium-dose group showed lower PHGDH gene methylation levels and higher PHGDH mRNA expression, serum PHGDH levels, and levels of serine and threonine (
P
<
0.05). Compared with the prescription-syndrome corresponding medium-dose group, the prescription-syndrome non-corresponding group showed higher PHGDH gene methylation levels and lower PHGDH mRNA expression, serum PHGDH levels, and levels of serine and threonine (
P
<
0.05).
Conclusion
2
Erchen Decoction
can inhibit PHGDH gene methylation in the aorta of mice with dyslipidemia phlegm-dampness obstruction syndrome, thereby upregulating PHGDH gene expression, reducing oxidative stress, and activating the serine metabolism pathway.
关键词
Keywords
references
LEI L , ZHAO N , ZHANG L , et al . Gut microbiota is a potential goalkeeper of dyslipidemia [J ] . Front Endocrinol (Lausanne) , 2022 , 13 : 950826 .
CHEN J , YE C , YANG Z , et al . The correlation between the traditional Chinese medicine (TCM) syndrome and the concentration of adiponectin and peroxynitrite in dyslipidemia patients [J ] . Eur J Integr Med , 2016 , 8 ( 6 ): 973 - 979 .
CHEN J , YE C , HU X , et al . Serum metabolomics model and its metabolic characteristics in patients with different syndromes of dyslipidemia based on nuclear magnetic resonance [J ] . J Pharm Biomed Anal , 2019 , 167 : 100 - 113 .
AMELIO I , CUTRUZZOLÁ F , ANTONOV A , et al . Serine and glycine metabolism in cancer . Trends Biochem Sci , 2014 , 39 ( 4 ): 191 - 198 .
SHU Y , HAO Y , FENG J , et al . Non-canonical phosphoglycerate dehydrogenase activity promotes liver cancer growth via mitochondrial translation and respiratory metabolism [J ] . EMBO J , 2022 , 41 ( 23 ): e111550 .
CHEN J , YE C , YANG Z , et al . Effects of Erchen Decoction on oxidative stress-related cytochrome P450 metabolites of arachidonic acid in dyslipidemic mice with phlegm-dampness retention syndrome: a randomized, controlled trial on the correspondence between prescription and syndrome [J ] . Evid Based Complement Alternat Med , 2022 : 1079803 .
JANG AY , LIM S , JO SH , et al . New trends in dyslipidemia treatment [J ] . Circ J , 2021 , 85 ( 6 ): 759 - 768 .
GITT AK , LAUTSCH D , FERRIÈRES J , et al . Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the dyslipidemia international study Ⅱ [J ] . Atherosclerosis , 2017 , 266 : 158 .
CHEN J , YE C , YANG Z , et al . Study on the effect of macrophages on vascular endothelium in mice with different TCM syndromes of dyslipidemia and its biological basis based on RNA-Seq technology [J ] . Front Pharmacol , 2021 , 12 : 665635 .
CHO HM , JUN DY , MABAE , et al . Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene [J ] . Gene , 2000 , 245 ( 1 ): 193 - 201 .
YOSHINO H , ENOKIDA H , OSAKO Y , et al . Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation [J ] . Mol Oncol , 2020 , 14 ( 9 ): 2190 - 2202 .
GUO WB , HUANG ZH , YANG C , et al . Down regulating PHGDH affects the lactate production of sertoli cells in varicocele [J ] . Reprod Biol Endocrinol , 2020 , 18 ( 1 ): 70 .
ZHANG B , ZHENG A , HYDBRING P , et al . PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis [J ] . Cell Rep , 2017 , 19 ( 11 ): 2289 - 2303 .
SIM WC , LEE W , SIM H , et al . Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease [J ] . Metabolism , 2020 , 102 : 154000 .
SAMANTA D , PARK Y , ANDRABI SA , et al . Retraction: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis [J ] . Cancer Res , 2024 , 84 ( 17 ): 2926 .